Equity Incentive Plan (Tables)

6 Months Ended

Jun. 30, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

A summary of the status of the Company’s option plans as of June 30, 2016 and changes during the period then ended is presented below:

	Six months ended June 30, 2016
	Unaudited
	Number of options			Weighted average exercise price
Outstanding at beginning of year		10,134,829		$	8.20
Granted		2,127,275			13.86
Exercised		(825,240	)		0.21
Forfeited and cancelled		(78,243	)		17.86

Outstanding as of June 30, 2016		11,358,621			9.77

Exercisable options		5,586,108			4.86

Vested and expected to vest		11,157,637		$	9.71

Schedule of Fair Value of Share Based Awards Using Black-Scholes Option Pricing Model

The fair value of share-based awards was estimated using the Black-Scholes option-pricing model for all grants with the following underlying assumptions:

	Six months ended June 30,			Year ended December 31,
	2016	2015		2015
	Unaudited			Audited
Expected term (years)	6.25		6.25	6.25
Expected volatility	59.80%-61.65%	62.5% - 65.8%		59.00%-65.80%
Risk-free interest rate	1.23%-1.88%	1.75% - 1.9%		1.74%-2.05%
Dividend yield	0%	0%		0%

Schedule of Non-cash Share-based Compensation Expense Related to Company's Equity-Based Awards

The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and six months ended June 30, 2016 and 2015 and the year ended December 31, 2015 was:

	Three months ended June 30,				Six months ended June 30,				Year ended December 31,
	2016		2015		2016		2015		2015
	Unaudited				Unaudited				Audited
Cost of revenues	$	170	$	6	$	311	$	19	$	174
Research, development and clinical trials		839		628		1,602		1,049		2,529
Sales and marketing		1,349		571		2,639		979		2,496
General and administrative		3,279		1,427		6,541		2,397		6,661
Total share-based compensation expense	$	5,637	$	2,632	$	11,093	$	4,444	$	11,860